Ang-2、Tie-2及VEGFR-2在大肠癌中的表达及与预后的关系

目的检测Ang-2、Tie-2及VEGFR-2在大肠癌组织中的表达,分析其与大肠癌复发、转移的关系。方法采用免疫组化SP法检测54例大肠癌组织、18例大肠癌旁组织中Ang-2、Tie-2、VEGFR-2的表达,探讨其与大肠癌预后的关系。结果①Ang-2、Tie-2、VEGFR-2在大肠癌组织中的阳性表达率分别为77.78%、74.07%及59.26%,显著高于癌旁正常组织的阳性表达率的27.28%、16.67%及22.22%,差异均有统计学意义(P<0.05)。②Ang-2、Tie-2及VEGFR-2在根治术后5年内发生复发转移者的阳性表达率分别为87.50%、75.00%和75.00%,显著高于未复发转移组阳性表达率(分别为44.44%及22.22%、33.33%),差异均有统计学意义(P<0.05)。③Kaplan-Meier生存分析结果表明,Ang-2、Tie-2及VEGFR-2表达阴性者5年生存率均明显高于阳性表达者(P<0.05)。结论 Ang、Tie-2及VEGFR-2的表达与大肠癌复发转移及预后密切相关,可作为预测侵袭转移及评估预后的分子生物学标志物。

The relationship between prognosis and expression of Ang-2,Tie-2 and VEGFR-2 in colorectal cancer

Objective To study the expression of Ang-2,Tie-2 and VEGFR-2 in colorectal cancer,and to analyze the relationship between them with recurrence,metastasis and prognosis of colorectal cancer.Methods The expressions of Ang-2,Tie-2 and VEGFR-2 were studied by using immunohistochemical SP in 54 cases with colorectal cancer and in 18 cases of neighboring colorectal cancer tissue.Results The positive rate of Ang-2,Tie-2 and VEGFR-2 in colorectal cancer tissue were respectively 77.78%,74.07% and 59.26%,which were significantly higher than those in neighboring colorectal cancer tissue(positive rate were respectively 27.28%、 16.67% and 22.22%)(P<0.05).The positive rate of Ang-2,Tie-2 and VEGFR-2 in patients who had recurrence metastasis after curative operation within 5 years were respectively 87.50%,75.00% and 75.00%,which were obviously higher than those in non-recurrence metastasis groups positive expression(positive rate were respectively 44.44%,22.22% and 33.33%)(P<0.05).The results of Kaplan-Meier survival analysis showed that five-year overall survival rates of patients who had negative expression of Ang-2,Tie-2 and VEGFR-2 were obviously higher than those who had positive expression(P<0.05).Conclusion The expression of Ang-2,Tie-2 and VEGFR-2 are closely correlated to the recurrence metastasis and prognosis of colorectal cancer,all of them could be the molecular markers for both predicting invasion metastasis and assessing prognosis.